Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01261000 · ClinicalTrials.gov registry record · NA
Tissue Biomarker for Pegvisomant Action
A NA study, sponsored by Cedars-Sinai Medical Center.
- Completed
- Registry status
- NA
- Development phase
- 8
- Enrollment target
NCT01261000 is a NA study that has completed, run by Cedars-Sinai Medical Center. The registered enrollment target is 8 participants.
The verdict
NCT01261000, a NA study, has completed, sponsored by Cedars-Sinai Medical Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 8 participants
- Enrollment target
Study Summary
Acromegaly is a disease of the pituitary gland that involves overproduction of growth hormone. Pegvisomant works by blocking binding of GH to receptors found in tissues throughout the body. Human studies have evaluated pegvisomant action by measuring reduction of IGF-I levels in the blood. However, no studies have evaluated the effects of blocking GH receptors in tissues. In this study, we will study tissue biomarkers for pegvisomant action in GH and IGF-I dependent signaling pathways in colon tissue of patients with acromegaly treated with pegvisomant.
Interventions
- DRUG Pegvisomant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2010-11 |
| Est. Completion | 2013-12 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01261000
The ClinicalTrials.gov registry entry for NCT01261000 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cedars-Sinai Medical Center, which has 339 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pegvisomant is the first listed.
NCT01261000 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01261000 about?
NCT01261000 is a clinical study titled "Tissue Biomarker for Pegvisomant Action". Acromegaly is a disease of the pituitary gland that involves overproduction of growth hormone. Pegvisomant works by blocking binding of GH to receptors found in tissues throughout the body. Human studies have evaluated pegvisomant action by measuring reduction of IGF-I levels in the blood. However, ...
What is the current status of trial NCT01261000?
This trial is currently completed. It is a NA study. The enrollment target is 8 participants. The study started on 2010-11. Estimated completion is 2013-12.
What interventions are being tested in trial NCT01261000?
The interventions under investigation include: Pegvisomant (DRUG).
Who is sponsoring clinical trial NCT01261000?
This trial is sponsored by Cedars-Sinai Medical Center, which has 339 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.